Froniglutide

弗洛格鲁肽

Report date: 2023/05/05 20:00:40

Base Information

Drug NameFroniglutide
Drug Alias NameGlymeraPB-1023GLP-1-ELP-120PF-1801
ClassificationBiologics > Protein drugs > Recombinant polypeptide
Mechanisms of ActionGlucagon-like peptide 1 receptor agonists
TargetsGlucagon-like peptide 1 receptor
Therapy Area/IndicationsDiabetes Mellitus, Type 2DermatomyositisPolymyositis +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSouth Korea
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesPhasebio Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesImmunoForge Co Ltd
Inactive CompaniesPhasebio Pharmaceuticals Inc
Active IndicationsDermatomyositisPolymyositisMyositis
Inactive IndicationsDiabetes Mellitus, Type 2

Other Information

ATC CodeN/A
Related LinksN/A